SAN
FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon
Biopharma, an innovator in developing therapeutic antibodies and
fusion proteins, will present its latest breakthrough
immunocytokine, FP008, on Jan 14,
2025, at the Biotech Showcase investor conference, following
J.P. Morgan Healthcare Week. This bifunctional anti-PD-1/IL-10M
fusion protein is designed to address populations refractory to
anti-PD-1 therapies. The presentation will introduce Fapon
Biopharma's continued strength and innovation in the development of
anticancer drugs.
FP008 is a proprietary and patented drug candidate using Fapon
Biopharma's cutting-edge antibody technology. As a first-in-class
biologic, FP008 uniquely combines an engineered IL-10
monomer (IL-10M) with an anti-PD-1 antibody, significantly
reducing the challenging toxicity associated with wild-type IL-10,
while activating IL-10M at the target site. This represents a
critical advancement in the field of immuno-oncology. FP008 not
only inhibits exhausted CD8+ T cells apoptosis and
enhances their functional activity in vitro, but also
significantly increases the proportion of CD8+ T
cells in tumor microenvironment, exhibiting a potent
anti-tumor effect in vivo. Additionally, FP008 has demonstrated
excellent druggability and good tolerability in cynomolgus
monkeys toxicity studies at doses up to 10 mg/kg, confirming
its viability as a candidate drug.
"FP008 represents a significant leap forward in our quest
to develop more effective and safer immunotherapies for cancer
patients," says Max Wang, Business Development
Director at Fapon Biopharma. "By addressing the critical
unmet need of PD-1 therapy-resistant tumors, FP008 has the
potential to transform treatment paradigms and improve outcomes for
patients who have limited options."
Fapon Biopharma plans to submit an Investigational New Drug
(IND) application for FP008 to the U.S. Food and Drug
Administration (FDA) in early 2025. The company remains committed
to developing more effective and accessible therapeutics through
consistent innovation and collaboration. Fapon Biopharma aims to
present FP008 to a global audience and seek strategic partners to
drive its development, ultimately benefiting cancer patients
worldwide.
Biotech Showcase Presentation Information
Title: Overview of Fapon Biopharma and IL-10 Antibody Fusion
Programs
Summary: This presentation highlights Fapon Biopharma's
integrated platforms for innovative biologics development, with a
focus on FP008, a novel bifunctional anti-PD-1/IL-10M fusion
protein designed to address anti-PD1 refractory/resistance
populations. Fapon Biopharma seeks global partners for licensing
and co-development opportunities.
Speaker: Max Wang
Date: Tuesday, January 14 2025
Time: 3:45PM
Track: Franciscan B (Ballroom Level)
About Fapon Biopharma
Fapon Biopharma specializes in discovering and developing
biologics for treating cancers, autoimmune diseases, and other
conditions with unmet medical needs. Leveraging advanced
technologies, Fapon has built sophisticated drug discovery
platforms, including an antibody discovery platform based on
leading mammalian cell display technology, a platform for
generating IL-10M fusion proteins, and a platform for developing
multispecific antibodies using Fibody and nanobodies. With a
differentiated pipeline of leading drug candidates, Fapon has
established capabilities across the entire drug development
process, from discovery and preclinical research to Chemistry,
Manufacturing and Controls (CMC) and early clinical development.
Committed to innovation, Fapon strives to deliver safer, more
efficacious, affordable, and accessible biologics for everyone.
Website: https://en.faponbiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fapon-biopharma-introduces-fp008-at-biotech-showcase-a-safer-and-more-effective-immunotherapy-for-refractory-cancers-302341164.html
SOURCE Fapon Biopharma
